Participant flow18

How many started, completed or left each group, period by period.

1 to 18 of 18

Period	Milestone	Group	Participants
Double Blind	STARTED	High Dose Ifetroban	18
Double Blind	STARTED	Low Dose Ifetroban	12
Double Blind	STARTED	Placebo	11
Double Blind	COMPLETED	High Dose Ifetroban	13
Double Blind	COMPLETED	Low Dose Ifetroban	9
Double Blind	COMPLETED	Placebo	8
Double Blind	NOT COMPLETED	High Dose Ifetroban	5
Double Blind	NOT COMPLETED	Low Dose Ifetroban	3
Double Blind	NOT COMPLETED	Placebo	3
Open Label Extension	STARTED	High Dose Ifetroban	13
Open Label Extension	STARTED	Low Dose Ifetroban	9
Open Label Extension	STARTED	Placebo	8
Open Label Extension	COMPLETED	High Dose Ifetroban	10
Open Label Extension	COMPLETED	Low Dose Ifetroban	7
Open Label Extension	COMPLETED	Placebo	8
Open Label Extension	NOT COMPLETED	High Dose Ifetroban	3
Open Label Extension	NOT COMPLETED	Low Dose Ifetroban	2
Open Label Extension	NOT COMPLETED	Placebo	0

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03340675/flow